hotspot -WSS

hotspot

author：fashion 2025-09-29 21:25:54 - browse：9

Adam's take main illustration — Molly Ferguson/STAT

Cassava Sciences has long claimed its experimental drug, called simufilam, slows the cognitive decline of people with Alzheimer’s. On Friday, we learned how: The company recruited a large number of people into its clinical trial who don’t have Alzheimer’s.

People who almost certainly had Alzheimer’s were also included in the study, but in this group, a placebo outperformed Cassava’s drug.

The conclusion, of course, is obvious: Simufilam is inactive. It’s an inert compound no more effective than a placebo. Cassava’s assertion that simufilam is showing “disease-modifying activity” falls apart given its study was opened to people who should have been ineligible because they were misdiagnosed with Alzheimer’s. Whether that was done intentionally or unwittingly isn’t known, but it’s certainly troubling and makes the case for immediate, regulatory intervention even stronger.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections
Next article： Live blog: Hearing on CRISPR

entertainment

leisure time

WSS

After Sarepta trial failure, Duchenne families brace for more debate

What is microchimerism and how does it affect maternal health?

Live blog: Hearing on CRISPR

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

Readout Newsletter: New research from Sanofi, Regeneron, etc.

Brain injuries and the importance of a second opinion

leisure time

hotspot

explore

Affirmative action in medical school literally saved lives

WHO may add ‘noma' to its list of neglected tropical diseases

Drug repurposing or repositioning? The language matters

Telehealth options flood the market as retailers push virtual care

Activists slam private health insurers over coverage restrictions

Readout Newsletter: XBI biotech index, Akero Therapeutics

The cancer drug shortage isn’t new — and neither are the solutions

Key Senate panel to consider PBM, drug pricing reform package

Activists slam private health insurers over coverage restrictions

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

leisure time

Traditional Chinese medicine benefits explored in new JAMA study

Bill would allow buprenorphine prescription for addiction via telehealth

Traditional Chinese medicine benefits explored in new JAMA study

Traditional Chinese medicine benefits explored in new JAMA study

Inari Medical to buy amputation prevention company LimFlow

After Sarepta trial failure, Duchenne families brace for more debate

entertainment

entertainment

leisure time

Wikipedia